Latent autoimmune diabetes in adults (LADA) is still a poorly characterized entity. However, its prevalence may be higher than that of classical type 1 diabetes. Patients with LADA are often misclassified as type 2 diabetes. The underlying autoimmune process against β-cell has important consequences for the prognosis, comorbidities, treatment choices and even patient-reported outcomes with this diabetes subtype. However, there is still an important gap of knowledge in many areas of clinical relevance. We are herein focusing on the state of knowledge of relevant clinical issues than may help in the diagnosis and management of subjects with LADA.
Keywords: Adults; Clinical management; Diabetes complications; Diabetes mellitus; Diagnosis; Glutamic decarboxylase autoantibodies (GADA); LADA; Latent autoimmune diabetes in adults; Patient-reported outcomes; Quality of life; Treatment.